Francesco Passamonti

Varese, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 303 publications

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 30, 2026

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 02, 2026

Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results.

Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results.

Journal: Future oncology (London, England)

Published: May 22, 2026

Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.

Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.

Journal: Leukemia & lymphoma

Published: May 18, 2026

Adding transcriptomic features to MF prognostic models.

Adding transcriptomic features to MF prognostic models.

Journal: Blood

Published: May 07, 2026

Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi.

Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi.

Journal: British journal of haematology

Published: April 22, 2026

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Journal: Future oncology (London, England)

Published: March 07, 2026

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

Journal: American journal of hematology

Published: January 30, 2026

Mixed Type Autoimmune Hemolytic Anemia: Clinical Severity and Treatment Patterns in a Large Observational Study.

Mixed Type Autoimmune Hemolytic Anemia: Clinical Severity and Treatment Patterns in a Large Observational Study.

Journal: American journal of hematology

Published: January 08, 2026

Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.

Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.

Journal: The New England journal of medicine

Published: December 30, 2025

Clinical heterogeneity and outcome of acquired PRCA: a multicenter European study.

Clinical heterogeneity and outcome of acquired PRCA: a multicenter European study.

Journal: Blood advances

Published: December 24, 2025

Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.

Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.

Journal: Blood advances

Published: December 24, 2025

Showing 1-12 of 303

Last Updated: 09/26/2026